Johnson & Johnson Q3 2025 Earnings Recap

Johnson & Johnson's Q3 2025 performance demonstrates strong operational growth across its business sectors, with a 5.4% increase in sales, underscoring the company's successful innovation strategy and market resilience.

Key Takeaways

• Innovative Medicine achieved operational sales growth of 5.3%, propelled by robust performance from 11 key brands, including a 40% surge in TREMFYA sales.
• MedTech saw even higher operational growth of 5.6%, fueled by improvements in all subdivisions and the planned separation of the Orthopaedics business to enhance focus on high-growth areas.
• Oncology sales rose nearly 20%, driven by market-leading products like DARZALEX and CARVICTI, which now stands as the most successful CAR T therapy launch globally.
• The FDA approval of Inlexo for bladder cancer treatment showcases J&J's innovative capabilities and solidifies potential $5 billion annual peak sales for the product.
• J&J is expanding its immunology portfolio, with a strong forecast for TREMFYA, which has gained significant market share within its first year of launch.